Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18150326 | 1.00 | P2RX7 (0.36) | P2RX7CCNCCDK8RIPK1HDAC6 | |
| SCHEMBL18151371 | 0.86 | RIPK1 (0.34) | RIPK1HDAC6HDAC1HDAC8NR3C2 | |
| SCHEMBL18150810 | 0.85 | P2RX7 (0.36) | P2RX7CCNCCDK8RIPK1HDAC6 | |
| SCHEMBL18150918 | 0.83 | RIPK1 (0.34) | RIPK1HDAC6HDAC1HDAC8NR3C2 | |
| SCHEMBL18153327 | 0.80 | TNF (0.39) | — | |
| SCHEMBL18150892 | 0.80 | TNF (0.39) | — | |
| SCHEMBL18151011 | 0.80 | RIPK1 (0.40) | RIPK1 | |
| SCHEMBL18151114 | 0.80 | RIPK1 (0.40) | RIPK1 | |
| SCHEMBL38651796 | 0.79 | TNF (0.35) | P2RX7CCNCCDK8HDAC6HDAC1 | |
| SCHEMBL18151059 | 0.79 | P2RX7 (0.35) | P2RX7CCNCCDK8HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| WO-2016168641-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | P2RX7 359/4885CCNC 1982/4885CDK8 913/4885 |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | P2RX7 359/4885CCNC 1982/4885CDK8 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.